2023Corporate Report Online Version
Dedicated to the Fight against Disease and Pain
For more than 300 years, since its founding in 1717, ONO has move forward, driven by its commitment to the health of patients. We still continue to unite our efforts in meeting the challenge of discovering our own innovative drugs.
Message and Round-table Discussion
Round-table Discussion with Outside Officers
Reinforcing the governance system
and accelerating sustainable
management to achieve sustainable growth
Four Outside Directors and Outside Audit & Supervisory Board members discussed ONO’s governance, compliance system, and outlook for sustainable growth.
Round-table Discussion of Diversity, Equity, and Inclusion (DE&I)
Sustainable growth through “difference” × “unity”
Outside Directors and employees knowledgeable of DE&I exchanged opinions regarding promoting female employee participation and respect for diversity in order to become an appealing organization that attracts people.
Strengths Supporting Value Creation In this section, we look at important business resources and initiatives to reinforce those in order to achieve sustainable growth.
We are actively moving forward with open innovation in partnership with such entities as leading academic institutions and bio-venture companies to discover innovative new drugs.
Our goal is to contribute to even more patients through drugs in the oncology, immune system disease, and specialty fields.
Note: Unless noted individually, data is for FY2022
Conditioned on a patient first perspective, we work to discover innovate new drugs and to maximize their product value.
By sharing the opinions received from patients and the medical field, the whole company has united to improve the wellbeing of patients and their families.
Note: Unless noted individually, data is for FY2022.Market sales and class share rankings are based on external data.
In order to continue to generate sustainable growth as a R&D-based pharmaceutical company that creates innovative drugs, we are not only accelerating the training and recruiting of talent who support the company but only working to foster an organizational culture with high employee engagement.
*1 Future executive talent, globally competent talent, digital talent, core innovation talent
*2 Venue for voluntary challenge of putting what employees have learned and experienced into practice
Note: Unless noted individually, data is for FY2022.
Initiatives Related to Business Strategy and Material Issues Having included important management issues into our 18 material issues, we are moving forward with a wide range of measures to implement our growth strategy and create value.
Our mission is to provide new value to patients through the creation of innovative drugs.
We are striving to create value required by companies and society, which includes strengthening R&D, expanding our pipeline, building our own marketing operations in U.S. and Europe to deliver medicines to more patients, and further expanding our business domain.
- 1Creation of Innovative Drugs
- 2Pipeline Expansion
- 3Maximization of Product Value
- 4Realization of Direct Sales in the US and Europe
- 5Expansion of Business Domains
Foundation for Value Creation
A foundation for creating value is important to generate sustainable growth and provide society with value, such as innovative drugs.
We consider digital technology and IT that contributes to corporate transformations; stronger financial capital, the resource for growth; greater human resources who contribute to transforming the company into a Global Specialty Pharma; an intellectual property strategy, which is indispensable for a pharmaceutical company; and partnerships with parties outside the company, which includes open innovation, the lifeline for corporate growth, as this foundation, and focus on achieving each one.
- 6Corporate Transformation through Digital & IT
- 7Strengthening of Financial Capital
- 8Expansion of Human Capital
- Round-table Discussion of Diversity, Equity, and Inclusion (DE&I)
- 9Intellectual Property Strategies
- 10Open Innovation
- 11Promotion of Diverse Partnerships
We also consider protecting the value we have created as a pharmaceutical company and cultivated to date as an important initiative.
Ensuring the reliability and safety of our products and possessing a stable supply system are indispensable for delivering the innovative drugs we create to more patients. We also recognize that the supply chain, human rights, compliance, and the preservation of the environment are major requirements for corporate activities. We will steadily move forward with these initiatives to generate greater corporate growth.
- 12Assurance of Product Reliability and Safety
- 13Stable Supply of Products
- 14Protection of Environment
- 15Respect for Human Rights
- 16Thorough Compliance
- 17Supply Chain Management
- Social Contribution Activities
To enhance corporate value and generate sustainable grow, we must strengthen corporate governance that is centered on reinforcing the functions of the Board of Directors and Audit & Supervisory Board.
As for the Board of Directors and Audit & Supervisory Board, we are working to improve their effectiveness through various measures, moving forward with various initiatives, including those related to ensuring diversity of Directors and Audit & Supervisory Board members and reforming the remuneration system, and building a strong governance system.
- Round-table Discussion with Outside Officers
- Directors and Audit & Supervisory Board Members
- 18Strengthening of Corporate Governance
- Risk Management